Rational Design of an Epidermal Growth Factor Receptor Vaccine: Immunogenicity and Antitumor Research

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Epidermal growth factor receptor (EGFR) overexpression drives human epithelial tumor growth, invasion, and metastasis.
• Current passive EGFR-targeted therapies have significant limitations.
• Developing active immunotherapies is crucial for overcoming treatment challenges.

Purpose of the Study:

• To design and evaluate novel cancer vaccines targeting EGFR.
• To assess the immunogenicity and anti-tumor efficacy of EGFR epitope-based vaccines fused to the diphtheria toxin translocation domain (DTT).

Main Methods:

• Bioinformatics tools (NetMHCpan, IEDB Consensus) were used to select seven EGFR extracellular domain (ECD) epitope peptides (EG1-7).
• Selected peptides were fused to the DTT translocation domain.
• Vaccines were formulated with Alum and CpG adjuvants and tested in an A549 murine tumor model.
• Humoral and cellular immune responses, as well as anti-tumor efficacy, were assessed.

Main Results:

• DTT-fused EGFR epitope vaccines (DTT-EG3,5,6,7) successfully elicited specific humoral and cellular immune responses.
• Vaccines significantly suppressed tumor growth in both prophylactic and therapeutic settings in the mouse model.
• Specific epitopes EG3, EG5, EG6, and EG7 were identified as key components for active immunization.

Conclusions:

• The developed DTT-EG vaccines represent a promising active immunotherapy strategy for EGFR-overexpressing tumors.
• The vaccine design and fusion methodology offer a viable approach for developing novel cancer vaccines.
• This study highlights a potential new avenue for treating epithelial cancers driven by EGFR signaling.